Compare Gitlab Inc (GTLB) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs Novavax Inc — how do they compare? Gitlab Inc trades at $55.09 (market cap $8.92B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: Gitlab Inc is far larger — about 4.9× Novavax Inc's market cap, and Novavax Inc is more actively traded (6,198,505 versus 4,716,893). Which is the better fit depends on your goals — on Pluang, investors hold Gitlab Inc for 62 Days and Novavax Inc for 59 Days on average.
| GTLB | NVAX | |
|---|---|---|
Market Cap | $8.92B | $1.82B |
Volume | 4,716,893 | 6,198,505 |
Sector | Technology | Health |
52-Week High | $53.56 | $12.56 |
52-Week Low | $19.42 | $6.22 |
Typical Hold Time | 62 Days | 59 Days |
Enterprise Value | $7.66B | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GitLab (GTLB) trades at $53.56, up 3.02% today and near its 52-week high, with strong technical momentum indicated by moving averages. The company shows impressive revenue growth, reaching $759 million in 2025, but remains unprofitable with a negative net income margin of -4.99%. Recent Q2 2026 earnings beat expectations, and the stock surged on raised guidance and AI-driven demand optimism.
Outlook: GitLab benefits from AI integration in software development and strong sales momentum, but high valuation multiples (P/E 521) and persistent losses pose risks. Analyst consensus is mixed with a $49.71 price target below current levels, suggesting cautious optimism amid execution challenges and competitive pressures.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
